Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-020-2558-4 http://scihub22266oqcxt.onion/10.1038/s41586-020-2558-4 32698191!ä!32698191 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2020 ; 585 (7826): 584-587 Nephropedia Template TP {{tp|p=32698191|t=2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates |pdf=|usr=}}{{32698191}} gab.com Text Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=32698191 #FOAvip Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease(1-3). Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-the virus that causes COVID-19-worldwide but there is no definitive evidence that HCQ is effective for treating COVID-19(4-7). Here we evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (Vero E6) but not in a model of reconstituted human airway epithelium. In macaques, we tested different treatment strategies in comparison to a placebo treatment, before and after peak viral load, alone or in combination with azithromycin (AZTH). Neither HCQ nor the combination of HCQ and AZTH showed a significant effect on viral load in any of the analysed tissues. When the drug was used as a pre-exposure prophylaxis treatment, HCQ did not confer protection against infection with SARS-CoV-2. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral drug for the treatment of COVID-19 in humans. Twit Text FOAVip Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=32698191 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32698191 #FOAvip English Wikipedia <ref>{{Cite pmid|32698191}}</ref> Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates #MMPMID32698191 Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Goncalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R Nature 2020[Sep]; 585 (7826): 584-587 PMID32698191show ga Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease(1-3). Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-the virus that causes COVID-19-worldwide but there is no definitive evidence that HCQ is effective for treating COVID-19(4-7). Here we evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (Vero E6) but not in a model of reconstituted human airway epithelium. In macaques, we tested different treatment strategies in comparison to a placebo treatment, before and after peak viral load, alone or in combination with azithromycin (AZTH). Neither HCQ nor the combination of HCQ and AZTH showed a significant effect on viral load in any of the analysed tissues. When the drug was used as a pre-exposure prophylaxis treatment, HCQ did not confer protection against infection with SARS-CoV-2. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral drug for the treatment of COVID-19 in humans. |Animals[MESH] |Azithromycin/pharmacology/therapeutic use[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Chlorocebus aethiops[MESH] |Coronavirus Infections/*drug therapy/pathology/physiopathology/*virology[MESH] |Cytokines/blood[MESH] |Disease Models, Animal[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/pharmacokinetics/pharmacology/*therapeutic use[MESH] |In Vitro Techniques[MESH] |Kinetics[MESH] |Macaca fascicularis[MESH] |Male[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/pathology/physiopathology/*virology[MESH] |Pre-Exposure Prophylaxis[MESH] |Respiratory Mucosa/cytology/drug effects/virology[MESH] |SARS-CoV-2[MESH] |Time Factors[MESH] |Treatment Failure[MESH] |Vero Cells[MESH]Hydroxychloroquine use against SARS-CoV-2 infection in non-human prima(epmc).pdf DeepDyve Pubget Overpricing